Skip to content

Osteogenic Action of a Biphasic Bioceramic With Statin in a Third Molar Extraction Model

Clinical Study to Analyze the Osteogenic Action of a Osteogenic Action of a Biphasic Bioceramic With Statin in a Third Molar Extraction Model (Galibone+) in Bone Regeneration Following the Extraction of Impacted Mandibular Third Molars

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06338241
Acronym
Galibone
Enrollment
30
Registered
2024-03-29
Start date
2024-03-02
Completion date
2025-09-02
Last updated
2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Loss, Regenerative Inflammation

Brief summary

The clinical study aims to assess the osteogenic effects of Galibone+ in bone regeneration post-extraction of impacted mandibular third molars.

Detailed description

With a focus on both clinical and radiological outcomes, the study seeks to compare the efficacy of Galibone+ against a standard material (Bio-Oss) through a double-blind, randomized split-mouth trial involving 30 patients. Variables including pain, inflammation, and post-surgical complications will be monitored during the initial seven-day follow-up, while bone volume reduction and mineral density will be evaluated radiographically over a six-month period. The study's findings promise to shed light on the potential of Galibone+ as a promising adjunct in enhancing bone regeneration following dental extractions, thereby advancing oral surgical practices and patient outcomes.

Interventions

COMBINATION_PRODUCTBiphasic bioceramic of tricalcium phosphate and hydroxyapatite with simvastatin

The intervention description for Galibone+ in the study involves the application of this substance to promote bone regeneration following the extraction of impacted mandibular third molars. Galibone is indicated to treat segmental and cavity bone loss, aesthetic repairs and bone augmentations (such as inlay or onlay grafts); to fill dental alveolar bone; for the placement of dental implants; for the stabilization of osteotomies and prostheses in dentistry.

The intervention description for Bio-Oss in the study involves the application of this standard material to promote bone regeneration following the extraction of impacted mandibular third molars. Bio-Oss is a commonly used xenograft material known for its osteoconductive properties.

Sponsors

Universidad de Murcia
CollaboratorOTHER
Mario Pérez Sayáns
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants must be of legal age. * Participants must provide informed consent for participation in the study. * Participants must require extraction of both impacted mandibular third molars. * Both impacted molars must exhibit a similar level of complexity for extraction. * Participants must have no history of infection in the impacted molars prior to extraction. * Participants must not have any contraindications to undergoing oral surgical procedures (ASA I/II classification).

Exclusion criteria

* Participants with severe mental disorders that may impair their ability to provide informed consent or follow study instructions. * Participants currently receiving medications contraindicated for dental extractions. * Participants under the age of legal consent. * Participants who have undergone head and neck radiotherapy within the past 18 months.

Design outcomes

Primary

MeasureTime frameDescription
Bone Regeneration_Reduction in radiolucent volumeA) Immediately after extraction B) 1 month. C) 3 months. D) 6 monthsThis outcome measure involves assessing the degree of bone regeneration in the extraction socket following the extraction of impacted mandibular third molars. It will be evaluated through radiological imaging using CBCT scans at specified time points, including immediately post-extraction, at one month, three months, and six months post-extraction. Reduction in radiolucent volume within the extraction socket, indicating new bone formation (Hounsfield unit (HU)). High values mean more radiopacity and better regeneration.
Bone Regeneration_bone volumeA) Immediately after extraction B) 1 month. C) 3 months. D) 6 monthsThis outcome measure involves assessing the degree of bone regeneration in the extraction socket following the extraction of impacted mandibular third molars. It will be evaluated through radiological imaging using CBCT scans at specified time points, including immediately post-extraction, at one month, three months, and six months post-extraction. Evaluation of bone volume within the extraction site over time (mm3). The increase in bone volume means better regeneration.
Bone Regeneration_bone densityA) Immediately after extraction B) 1 month. C) 3 months. D) 6 monthsThis outcome measure involves assessing the degree of bone regeneration in the extraction socket following the extraction of impacted mandibular third molars. It will be evaluated through radiological imaging using CBCT scans at specified time points, including immediately post-extraction, at one month, three months, and six months post-extraction. Changes in bone density within the regenerated bone tissue (Hounsfield unit (HU)) High values mean more radiopacity and better regeneration.
Bone Regeneration_Fractal dimensionA) Immediately after extraction B) 1 month. C) 3 months. D) 6 monthsThis outcome measure involves assessing the degree of bone regeneration in the extraction socket following the extraction of impacted mandibular third molars. It will be evaluated through radiological imaging using CBCT scans at specified time points, including immediately post-extraction, at one month, three months, and six months post-extraction. Evaluation of bone morphology within the extraction site over time analyzing the fractal dimension (FD) FD can vary between 1 and 2, with 1 being a very simple fractal dimension (such as a straight line) and 2 being a more complex fractal dimension (such as a completely irregular surface).

Secondary

MeasureTime frameDescription
Post-surgical complications evaluated by presence or absense24 hours, 48 hours, 72 hours, and 7 daysMonitoring and recording of any complications following the extraction procedure, such as alveolitis, trismus, infection, and hematoma (presence/absence). The presence of complications is related to a worse prognosis.
Oral Health-related Quality of Life measured by OHIP-14 test24 hours, 48 hours, 72 hours, and 7 daysAssessment of the impact of treatment on patients' quality of life using validated instruments (OHIP-14). Lower scores: They indicate that the person experiences less impact of oral health problems on their quality of life. That is, they have fewer problems or feel less the impact of these problems in their daily lives. Intermediate scores: Suggest a moderate impact of oral health problems on quality of life. The person may experience some difficulties or discomfort related to their oral health, but they do not necessarily significantly affect their daily functioning. Higher scores: Indicate a significant impact of oral health problems on quality of life. The person may experience a wide range of problems that affect their general well-being, including pain, eating difficulties, sleep problems, etc.
Pain levels through visual analog scale24 hours, 48 hours, 72 hours, and 7 daysAssessment of pain experienced by participants using a visual analog scale (VAS) at various time points post-extraction. It comprehends values between 0-10, where 10 is the worst situation.
Clinical Inflammation evaluating by presence/absence24 hours, 48 hours, 72 hours, and 7 daysEvaluation of postoperative inflammation around the extraction site using clinical examination and assessment tools (presence/absence). The presence of inflammation means the worst prognosis.
Healing measured by healing index24 hours, 48 hours, 72 hours, and 7 daysThe healing progress will be assessed using the Healing Index (HI) developed by Hamzani & Chaushu (2018) and Landry (1988). The HI score ranges from 0 to 5, where 0 indicates poor healing and 5 indicates excellent healing. To ensure consistency and reliability in the assessment of healing, two independent researchers will evaluate the healing progress for all participants. The level of agreement between the researchers will be assessed using Cohen's Kappa index (Mandrekar, 2011). A Cohen's Kappa index value of 0.91 was achieved for the assessment of inflammation level, indicating a high degree of agreement. Similarly, agreement levels exceeding 0.90 were obtained across all HI levels, demonstrating a high level of concordance in the assessment of healing progress.

Countries

Spain

Contacts

Primary ContactMARIO PEREZ SAYANS GARCIA, PHD, PHD
mario.perez@usc.es+34626233504

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026